Eyeon Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
The founder of Eyeon Therapeutics thinks that his firm will take giant steps forward in the next six months towards commercializing an over-the-counter nanotechnology-based eye drop for treating dry eye.
You may also be interested in...
Start-Up Previews (09/2007)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "The Eyes Still Have It," features profiles of Alacrity Biosciences, Eyeon Therapeutics, Mobius Therapeutics and OcuCure Therapeutics. Plus these Start-Ups Across Health Care: CyberHeart, GlycoVaxyn, TheraCardia and Vicus Therapeutics.
The Eyes Still Have It: Finding Cures For Diseases that Blind Remains Top Focus for Investors, Entrepreneurs
Over the past few years's there's been no shortage of venture capital investments in companies developing potential treatments for diseases of the eye. Still, investors continue to find entrepreneurs with innovative new approaches to treat age-related macular degeneration, glaucoma and other vision-imparing diseases.
MacuSight Inc.
MacuSight was founded by Frazier Healthcare Ventures to exploit the potential of rapamycin to treat age-related macular degeneration.